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a b s t r a c t 
Staphylococcus aureus is a premier human pathogen and the most common cause of osteoarticular, wound, 
and implanted device infections. We recently demonstrated S. aureus efﬁciently binds the classical comple- 
ment regulator C4b-binding protein (C4BP) inhibiting antibody-initiated complement-mediated opsoniza- 
tion. Here we identify S. aureus surface protein SdrE as a C4BP-binding protein. Recombinant SdrE and re- 
combinant bone sialoprotein-binding protein (Bbp), an allelic variant of SdrE, both efﬁciently bound to C4BP 
in heat-inactivated human serum. We previously described SdrE as binding alternative pathway regulator 
factor H. Recombinant SdrE and Bbp efﬁciently bound C4BP and factor H in serum without apparent interfer- 
ence. Gain of function studies utilizing Lactococcus lactis clones expressing SdrE or Bbp increased serum C4BP 
and factor H binding, compared with empty-vector control (WT) approximately 2-fold. Correspondingly, 
classical pathway-mediated C3-fragment opsonization and bacterial killing by human neutrophils decreased 
by half for L. lactis clones expressing SdrE or Bbp compared with WT. In summary, we identify SdrE and
allelic variant Bbp as S. aureus surface proteins that bind the complement regulator C4BP inhibiting classical 
pathway-mediated bacterial opsonization and killing. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction 
Staphylococcus aureus is the preeminent human pathogen causing 
kin and skin-structure infections [ 9 ] as well as post-operative in- 
ections [ 12 ], in addition to being the major cause of many types 
f invasive bacterial infections [ 3 , 39 ]. Hospital- and community- 
ssociated MRSA infections continue to rise [ 16 ] making treatment 
f this pathogen ever more challenging. Additionally, evidence sug- 
ests that wild-type infection does not yield protective immunity 
gainst repeated infection with the same strain [ 29 ] and all attempts 
o develop a successful vaccine against S. aureus have failed [ 7 ]. 
The lack of protective immunity from infection or immunization      
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Open access under CC BY-NC-ND licsuggests that antibody-mediated immunity against S. aureus is in- 
adequate. This is despite the fact that a wide variety of antibodies 
are generated by the human host during S. aureus infection [ 37 ] and 
many different immunogens have been tried as vaccines in a variety 
of combinations [ 33 ]. Antibody interactions with Fc receptors are al- 
tered by S. aureus expression of staphylococcal protein A (SpA) and Sbi 
[ 23 ], but antibody binding to the bacterial surface also initiates potent 
classical complement pathway-mediated host defenses including op- 
sonization and anaphylatoxin production [ 24 ]. Inhibition of classical 
complement pathway activation in the host is primarily regulated 
by C4b-binding protein (C4BP) by displacing C2a from the classical 
C3 convertase and facilitating factor I-mediated cleavage of C4b to 
inactive forms [ 6 , 13 , 14 ]. Surface recruitment of C4BP as an immune 
evasion strategy has been demonstrated for several pathogenic bacte- 
ria including Streptococcus pyogenes [ 1 , 21 ], Streptococcus pneumoniae 
[ 8 ], Borrelia burgdorferi [ 30 ], and Neisseria meningitidis [ 20 ]. 
We have recently shown that the host complement regulator of 
classical pathway activation C4BP is recruited to the surface of S. 
aureus increasing degradation of the classical C3 convertase and con- 
tributing to C4b cleavage resulting in decreased opsonization by C3b ense.
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Fig. 1. Identiﬁcation of SdrE as a binding partner for C4BP. (A) S. aureus cell wall 
preparation fractions separated by size-exclusion chromatography then assayed for 
C4BP binding by dot blot. (B) Cell wall proteins from concentrated fractions were 
separated by SDS-PAGE and visualized by total protein stain (left). Blotted proteins 
were overlayed with serum (CVF-treated) and then probed for bound C4BP (right). 
Three bands were excised and analyzed by mass spectrometry. (C) Peptide coverage 
map for SdrE peptides identiﬁed by mass spectrometry in bold and underlined. 
 
 
 
 
 
 
 
 [ 18 ]. These results suggested that S. aureus recruitment of C4BP to its
surface likely contributes to the inhibition of antibody-initiated clas-
sical complement pathway activation, a mechanism that may result
in lack of protective adaptive immunity after infection or immuniza-
tion. 
Here we identify S. aureus surface proteins that bind to C4BP
and show that bacterial expression of these proteins alters classical
complement pathway-mediated opsonization and bacterial killing.
Identiﬁcation of C4BP-binding surface proteins that inhibit antibody-
initiated complement activation and immune effectors provides an
opportunity to develop novel strategies to increase vaccine effective-
ness against S. aureus . 
2. Material and methods 
2.1. Ethics Statement 
Human blood was obtained from four healthy volunteers for gen-
erating serum and neutrophils used as reagents in these studies.
Eastern Virginia Medical School IRB approved this study protocol:
02–06-EX-0216. Written informed consent was provided by study
participants. 
2.2. Bacteria and growth conditions 
S. aureus Reynolds strain was grown to mid-logarithmic phase in
Columbia 2% NaCl media at 37 ◦C, as described elsewhere [ 5 ]. Lac-
tococcus lactis strains that constitutively express the staphylococcal
surface proteins SdrE, Bbp, or that contain the empty vector pKS80 are
described elsewhere [ 26 , 36 ]. L. lactis were grown in M17 broth con-
taining 0.5% glucose and 5 μg / ml of erythromycin at 30 ◦C without
shaking, as previously described [ 32 ]. MRSA strains from the Nebraska
Transposon Mutant Library, described elsewhere [ 11 ], were obtained
from NARSA. 
2.3. Buffers 
Binding experiments were performed with GVBS + + buffer (VBS
with 0.1% gelatin, 0.15 mM CaCl 2, and 1.0 mM MgCl 2 ), or EDTA-
GVBS − − buffer (VBS with 0.1% gelatin and 0.01 M EDTA). 
2.4. Human serum and puriﬁed complement proteins 
Normal human serum (NHS) was prepared as previously described
[ 4 ] from the blood of four healthy donors and pooled. Blood was ob-
tained with consent under an IRB-approved protocol (Eastern Virginia
Medical School IRB 02–06-EX-0216). Heat-inactivated sera were gen-
erated by incubating NHS at 56 ◦C for 30 min. Cobra Venom Factor
(CVF) treated sera was generated by incubating NHS with CVF (Comp
Tech) at 20 μg / ml for 1 h at 37 ◦C. Heat-inactivated and CVF-treated
sera were conﬁrmed to have no complement activity in a CH50 assay.
Factor B depleted sera and puriﬁed C4b Binding Protein (C4BP) were
obtained commercially (Comp Tech). Total IgG in our pooled serum
was measured at 16.5 mg / ml by ELISA, as previously described [ 10 ].
IgG binding to S. aureus was estimated by incubating 10 10 CFU of a
Spa-deﬁcient strain (Nebraska Transposon Mutant Library) with 1 ml
of heat-inactivated pooled human serum, stripping bound antibody,
and measurement by ELISA. We measured 0.0257 mg of IgG bound
10 10 CFU, or about 0.15% of total IgG in the serum. Relative amount
of anti-SdrE antibody present in the serum was performed by se-
rial dilution comparing antibody binding to rSdrE or a total cell wall
preparation (Spa-deﬁcient strain) in a modiﬁed ELISA-type assay. Ap-
proximately 0.019% of IgG in the serum bound to rSdrE compared to
a total cell wall preparation. 2.5. Recombinant proteins 
Recombinant SdrE (rSdrE), recombinant bone sialoprotein-
binding protein (rBbp), and recombinant ClfA (rClfA) were expressed
as His-tagged proteins containing their respective unique A regions
in an Escherichia coli expression system, as described elsewhere
[ 26 , 27 , 36 ]. Brieﬂy, recombinant proteins were puriﬁed from cell
lysates by nickel column chromatography and veriﬁed by anti-His
tag dot blots and SYPRO Ruby (Invitrogen) stained SDS-PAGE. 
2.6. Isolation of cell wall proteins binding C4BP 
Cell wall extracts were prepared and separated by size exclu-
sion chromatography as described previously [ 19 ]. Brieﬂy, cell wall
116 Pamela S. Hair et al. / Results in Immunology 3 (2013) 114–121 
Fig. 2. ELISA-type binding assays for C4BP and factor H with recombinant SdrE and recombinant Bbp. (A) C4BP in heat-inactivated serum binding rSdrE, rBbp, or rClfA ( n = 5). (B) 
Time-course of C4BP in heat-inactivated serum binding rSdrE or rBbp ( n = 4). (C) C4BP in normal human serum (NHS) or heat-inactivated serum binding rSdrE. (D) Puriﬁed C4BP 
binding rSdrE or rBbp ( n = 4). (E) Factor H in heat-inactivated serum binding rSdrE or rBbp ( n = 5). (F) Time-course of Factor H in heat-inactivated serum binding rSdrE or rBbp ( n 
= 3). Data are the means of results of independent experiments. Error bars denote SEM. 
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treparations were generated from mid-logarithmic phase S. aureus 
eynolds using lysostaphin in a protoplast stabilizing rafﬁnose buffer 
ith DNAse and protease inhibitors. Separation by size-exclusion col- 
mn chromatography was performed using a HiPrep 16 / 60 Sephacryl 
olumn equilibrated with PBS. Fractions were dot blotted and blocked 
ith 3% BSA / TBS and washed with TBS-Tween. Blot overlay was per- 
ormed with 10% CVF-NHS for 2 h and then probed with a mouse anti- 
uman C4BP antibody (Quidel) followed by a goat anti-mouse HRP an- 
ibody (Sigma-Aldrich). Fractions that bound serum C4BP were then identiﬁed by enhanced chemiluminescence (ECL). These fractions of 
interest were further analyzed by SDS-PAGE with SYPRO Ruby (In- 
vitrogen) total protein stain, or 10% CVF-NHS overlay Western blot. 
Overlay blot controls were performed without serum or without pri- 
mary antibody, yielding negative results for each. 
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Fig. 3. Serum C4BP binding to L. lactis expressing SdrE, or Bbp, or empty vector control. (A) SdrE and Bbp expression by L. lactis strains assayed by modiﬁed ELISA. (B) C4BP in 
10% heat-inactivated serum binding to L. lactis strains at 30 min assayed by dot blot of stripped surface proteins ( n = 4). (C) Factor H in 10% heat-inactivated serum binding L. 
lactis strains at 30 min assayed by dot blot of stripped surface proteins ( n = 4). (D) C4BP and factor H in 20% heat-inactivated serum binding to SdrE-expressing L. lactis over 30 
min assayed by dot blot of stripped surface proteins ( n = 4). (E) C4BP in 10% heat-inactivated serum binding to S. aureus strains including wild type (WT), SdrE-deﬁcient (SdrE −), 
Sbi-deﬁcient (Sbi −), CHIPS-deﬁcient (Chs −), and capsule-deﬁcient (Cap50 −) assayed by dot blot of stripped surface proteins ( n = 4). Data are the means of results of independent 
experiments. Error bars denote SEM. 
 
 
 
 
 
 
 
 2.7. Mass spectrometry identiﬁcation 
Protein bands were excised from SYPRO-Ruby stained SDS-PAGE
gels and processed for liquid chromatography electrospray ioniza-
tion tandem mass spectrometry (LC-ESI-MS / MS) on a linear trap
quadrupole ion trap (LTQ) mass spectrometer (Thermo Fisher) as
previously described [ 17 , 19 , 38 ]. The acquired data was processed byXcalibur (Thermo Fisher) and the proteins were identiﬁed using Mas-
cot Daemon version 2.2.03 (Matrix Science, UK) software using the
latest version (2012 10) of the combined indexed Homo sapiens and S.
aureus sequences of the non-redundant Swiss-Prot protein database. 
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2.8. Alignment analysis 
Amino acid sequences of SdrE (GenBank accession # 
P 001331559 .) and Bbp (GenBank Accession # Q14U76.1 ) as well 
s human C4BP (GenBank Accession # AAA36507.1 ) and factor H 
GenBank Accession # P08603.4 ) were aligned using Clustal Omega 
 15 ]. 
.9. Binding assays 
Recombinant Bbp or SdrE was bound to 96-well Immulon II plates 
t 10 μg / ml in a carbonate coating buffer pH 9.6, and incubated 
vernight at 4 ◦C. The plates were then washed with 2 × PBS / 
% Tween-20 three times and blocked with 0.5% gelatin in PBS for 
 h at room temperature. The plates were washed again, and NHS, 
eat-inactivated sera, or pure C4BP were diluted in blocking buffer, 
itrated, and incubated for the time indicated at room temperature. 
fter washing, the plates were probed with chicken anti-human factor 
 antibody (Accurate Chemical), or the mouse anti-human C4BP anti- 
ody; antibodies were diluted to 1:1000 in blocking buffer and incu- 
ated for 1 h. Secondary probe was performed with goat anti-chicken 
RP antibody (Genway) or goat anti-mouse HRP antibody; antibod- 
es were diluted to 1:1000 in blocking buffer and incubated for 1 h. 
lates were washed and developed with TMB substrate (Thermo Sci- 
ntiﬁc) and stopped with 2.5 N H 2 SO 4 . Absorbance values were read 
t 450 nm. Values from control wells performed without primary an- 
ibodies yielded low background signals, which were subtracted out. 
.10. L. lactis expression of SdrE and Bbp 
Log phase L. lactis in coating buffer were used to coat an Immu- 
on II plate starting at 1.3 × 10 8 cells / ml then serial dilutions. After 
vernight at 4 ◦C, wells were washed and blocked with 0.5% gelatin 
n PBS for 2 h. After washing, wells were incubated with a chicken 
nti-SdrE / Bbp antibody diluted in block buffer, at 1:1000 for 1 h. The 
ells were then washed and incubated with anti-chicken HRP anti- 
ody (Genway) diluted in block buffer at 1: 1000 for 1 h . Wells were 
ashed and developed with TMB, as described above. 
.11. Factor H and C4BP binding L. lactis strains 
L. lactis strains were suspended at OD 600 = 4.0, of which 0.25 ml 
as diluted with heat-inactivated sera and GVBS + + buffer to a total 
olume of 0.5 ml and incubated for 30 min at 37 ◦C [ 32 ]. Bacteria were 
ashed with GVBS −− buffer, and surface proteins were stripped with 
0 μl of 2% SDS and boiled for 5 min. Samples were sedimented and 
upernatants recovered. 
.12. Factor H and C4BP quantitative dot blot 
C4BP dot blot has been previously described [ 18 ]. Brieﬂy, after 
dding samples and washing, the membrane was blocked with 3% 
SA, probed with a monoclonal mouse anti-C4BP primary antibody, 
nd then a HRP-labeled goat anti-mouse secondary antibody. The 
actor H dot blot was probed with a goat anti-human factor H antibody 
rimarily and a rabbit anti-goat HRP antibody secondarily. Puriﬁed 
actor H was used to generate a standard curve and detection was via 
CL. Quantity One software (Bio-Rad) was used to assign grey scale 
alues to the standard curve titrations and the samples so that a linear 
egression could be used to quantify the amount of C4BP or factor H 
n each sample. 
.13. C3 binding to L. lactis 
L. lactis strains were incubated with 10% factor B-depleted sera in GVBS + + buffer for 10 min at 37 ◦C. These cells were washed thor- 
oughly with GVBS −− buffer, and the cell pellets were resuspended 
in 50 μL of 25 mM methylamine to strip off covalently bound C3- 
fragments. Quantity of total C3-fragments was measured via C3 ELISA 
as previously described [ 17 ]. C3-fragments were qualitatively ana- 
lyzed by Western blot analysis, as previously described [ 17 ]. 
2.14. L. lactis killing assay 
The complement-mediated killing assay was performed as de- 
scribed previously [ 32 ]. Brieﬂy, in 1.0 ml total volume, 6 × 10 6 CFU L. 
lactis , 5 × 10 6 neutrophils and 10% factor B-depleted sera diluted in 
HBSS with Ca + + were tumbled at 37 ◦C. At 15 and 30 min, samples 
were diluted in sterile water and plated on GM17 agar supplemented 
with erythromycin. After overnight growth at 30 ◦C, colonies were 
counted. The number of bacteria killed was calculated by subtracting 
the bacterial count of the sample with neutrophils from the bacterial 
count of a matched base-line sample without neutrophils. Additional 
controls performed without serum yielded zero killing. 
2.15. Statistical analysis 
Means and standard error of the means (SEM) were calculated 
from ‘ n ’ independent experiments performed on separate days. Data 
were analyzed by student’s t test; calculated P values of ≤ 0.05 were 
considered statistically signiﬁcant. 
3. Results 
3.1. Identiﬁcation of S. aureus cell wall protein SdrE as a C4BP binding 
protein. 
In order to identify S. aureus cell wall proteins that bind C4BP we 
utilized methodology we have previously reported [ 19 , 32 ]. Brieﬂy, S. 
aureus cell wall preparations were generated, fractionated by column 
chromatography and analyzed by overlay C4BP dot blot ( Fig. 1 A). Cell 
wall fractions demonstrating the highest C4BP binding were concen- 
trated and assayed by serum C4BP overlay Western blot identifying 
three bands of interest ( Fig. 1 B). Control Western blots performed 
without serum overlay or without primary antibody were negative. 
Corresponding bands were excised from total protein stained SDS- 
PAGE gels and subjected to in gel digestion and mass spectrometry 
analysis (LC-ESI-MS / MS) in order to identify peptide sequences. All 
three bands of interest yielded multiple signiﬁcant identiﬁcations of 
peptides from the S. aureus cell wall protein SdrE ( Table 1 ). Peptide 
scores > 30 and Expect scores < 0.05 were considered signiﬁcant. 
These identiﬁed peptides yielded a peptide map for SdrE with 58% 
coverage of the non-SD-repeat region ( Fig. 1 C). 
We have previously reported identiﬁcation of SdrE as a S. aureus 
cell wall receptor for the host complement regulator factor H that 
decreases complement alternative pathway-mediated opsonization 
and bacterial killing [ 32 ]. The most common conﬁguration of C4BP 
is seven alpha chains and one beta chain [ 2 ]. The 1231 amino acid 
factor H and the 597 amino acid alpha-chain of C4BP are comprised 
of complement control protein (CCP) domains [ 22 ] with regions of 
limited homology (Supplemental Fig. S1A). 
3.2. Binding of C4BP or factor H with SdrE or Bbp. 
S. aureus bone sialoprotein-binding protein (Bbp) is an allelic 
variant of SdrE [ 35 ] with 75% sequence identity between the two 
molecules (Supplemental Fig. S1B). Thus, we analyzed the binding of 
C4BP and factor H to both SdrE and Bbp, as well as a control LPXTG- 
linked S. aureus surface protein, ClfA. C4BP in heat-inactivated serum 
was allowed to interact with surface-bound recombinant proteins for 
60 min in an ELISA-type assay. Heat-inactivated serum was used to 
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Table 1 
Mass spectrometry analysis of S. aureus cell wall protein binding C4BP. 
Mr (expt) Mr (calc) Peptide score Expect score Peptide sequence 
1213.3464 1213.5727 49 0.014 K.YRFDNLDSGK.Y 
1242.8066 1242.6860 48 0.018 R.LTLYSYIDKK.T 
1252.6867 1252.6340 51 0.0089 K.FETPTGYLPTK.V 
1385.2488 1384.6695 72 9.1e-05 K.VNSDQQLPQSNR.I 
1435.3694 1434.7090 78 2e-05 K.TATEDTSVILEEK.K 
1440.9608 1440.7460 78 2.3e-05 K.VIGTTTTDASGKYK.F 
1443.6196 1443.7933 79 1.8e-05 K.GIKDVTVTLQNEK.G 
1492.2922 1492.6028 69 0.00018 K.DADNMTLDSGFYK.T 
1594.4430 1593.7522 73 8.4e-05 K.VDIAGSQVDDYGNIK.L 
1603.4596 1602.8101 62 0.0011 K.LGNGSTIIDQNTEIK.V 
1764.2652 1763.8941 48 0.029 K.TVPNETSLNLTFATAGK.E 
1775.5260 1774.8962 69 0.00023 K.VYKVNSDQQLPQSNR.I 
1895.0746 1894.8756 62 0.0012 K.VNGTTDGEKDSNGSSVTVK.I 
1900.6288 1899.9003 78 3.4e-05 K.GHYEFGGLKDGETYTVK.F 
1931.1484 1931.0211 87 3.6e-06 K.DVTVTLQNEKGEVIGTTK.T 
1943.5350 1943.0000 96 5e-07 R.FAVAQPAAVASNNVNDLIK.V 
1957.3312 1956.8735 78 3.5e-05 K.YTPTSDGELDIAQGTSMR.T 
1964.6628 1963.9698 106 4.7e-08 K.NTTAEDKDSNGLTTTGVIK.D 
1992.8768 1992.0528 77 3.8e-05 K.LGNGSTIIDQNTEIKVYK.V 
2098.5814 2097.9167 82 1.6e-05 R.IYDFSQYEDVTSQFDNK.K 
2141.7474 2141.0205 69 0.0003 K.QITYTFTDYVDKYEDIK.S 
2146.6474 2146.0470 76 6.4e-05 K.DGETYTVKFETPTGYLPTK.V 
2173.6574 2173.1266 80 2.4e-05 K.LDEDKQTIEQQIYVNPLK.K 
2195.7294 2195.0706 98 3.9e-07 K.SATNTKVDIAGSQVDDYGNIK.L 
2226.5414 2225.9965 70 0.00028 K.IGDYVWEDVDKDGVQGTDSK.E 
2226.6934 2226.9957 84 1.1e-05 R.IYDFSQYEDVTSQFDNKK.S 
2246.0554 2246.1365 71 0.00022 K.MRFAVAQPAAVASNNVNDLIK.V 
2290.5614 2290.1005 93 1.3e-06 K.SFSNNVATLDFGDINSAYIIK.V 
2302.7994 2302.2056 59 0.0031 K.LDEDKQTIEQQIYVNPLKK.S 
2384.7054 2384.1536 69 0.00034 K.QITYTFTDYVDKYEDIKSR.L 
2554.9747 2554.2762 75 0.0001 K.VDNQVTDATNPKEPVNVSKEELK.N 
2576.0263 2576.2202 66 0.00078 K.SSTQQQQNNVTATTETKPQNIEK.E 
2679.6994 2679.2228 75 9.4e-05 K.FTDLDNGNYTVEFETPAGYTPTVK.N 
2766.0661 2766.3811 56 0.0086 K.NVIPSDLTDKNDPIDITDPSGEVIAK.G 
2971.6754 2971.3651 65 0.0011 K.YKFTDLDNGNYTVEFETPAGYTPTVK.N 
3038.1532 3038.3629 75 0.00011 K.VGDGKDNVAAAHDGKDIEYDTEFTIDNK.V 
3130.4722 3130.4830 64 0.0014 K.FETPTGYLPTKVNGTTDGEKDSNGSSVTVK.I 
3178.8622 3178.5517 85 1e-05 K.VDIAGSQVDDYGNIKLGNGSTIIDQNTEIK.V 
3439.2682 3439.5461 60 0.0038 K.NTTAEDKDSNGLTTTGVIKDADNMTLDSGFYK.T 
3482.7922 3482.5292 94 1.4e-06 K.QDDATTSDNKEVVSEAENNSTTENDSTNPIKK.E 
3571.1422 3570.7464 70 0.00038 K.VDIAGSQVDDYGNIKLGNGSTIIDQNTEIKVYK.V 
3593.4952 3593.6546 65 0.0012 K.VNSDQQLPQSNRIYDFSQYEDVTSQFDNKK.S 
3780.7162 3780.8541 57 0.0085 K.SATNTKVDIAGSQVDDYGNIKLGNGSTIIDQNTEIK.V 
3799.4212 3798.6697 116 1e-08 R.TTDKYGYYNYAGYSNFIVTSNDSGGGDGTVKPEEK.L 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 prevent C4BP or factor H from binding with deposited C4b or C3b, re-
spectively. C4BP in heat-inactivated serum bound recombinant SdrE
and Bbp in a dose-dependent manner compared with minimal bind-
ing for rClfA ( Fig. 2 A). Time-course experiments were performed with
25% heat-inactivated serum allowing C4BP to bind to recombinant
proteins in ELISA-type assays. C4BP in heat-inactivated serum demon-
strated time-dependent binding to rSdrE and rBbp ( Fig. 2 B). Testing
C4BP binding to rSdrE using either normal human serum (NHS) or
heat-inactivated serum yielded similar binding ( Fig. 2 C). In previously
published experiments testing C4BP binding to the S. aureus surface,
heat-inactivated serum demonstrated decreased C4BP binding com-
pared with NHS [ 18 ]. Puriﬁed C4BP demonstrated dose-dependent
binding to rSdrE as well as rBbp ( Fig. 2 D). Half-maximal binding for
pure C4BP was observed at 15 nmol / l for rSdrE and 30 nmol / l for rBbp,
where the recombinant proteins were coated at 10 μg / ml. These ﬁnd-
ings suggest that C4BP may have a have a higher afﬁnity for SdrE than
Bbp. Absorbance values for 50% heat-inactivated serum showed a 3-
fold increase ( p = 0.02) for factor H binding to rBbp compared with
fH binding to rSdrE ( Fig. 2 E); however half-maximal binding values
were similar. Time-course experiments also suggested increased ab-
sorbance values for factor H in heat-inactivated serum binding to
rBbp compared with rSdrE ( Fig. 2 F). These ﬁndings suggest that Bbp,
in addition to SdrE, may also be a factor H-binding protein.  3.3. Binding of C4BP and factor H to L. lactis expressing SdrE or Bbp. 
In order to evaluate the binding of C4BP to SdrE or Bbp expressed
on a bacterial surface we used gain-of-function L. lactis clones ex-
pressing SdrE, or Bbp, or containing an empty vector. L. lactis clones
were measured for SdrE and Bbp expression using whole cells in a
modiﬁed ELISA-type assay ( Fig. 3 A) demonstrating signiﬁcant expres-
sion compared with empty vector. L. lactis clones were incubated in
heated-sera and then stripped of surface-bound proteins which were
measured by dot blot assays. Control dot blots were performed for
L. lactis without serum or without primary antibody demonstrating
minimal background. L. lactis clones in 10% heated-sera over 30 min
bound more C4BP when expressing SdrE ( p = 0.04) or Bbp ( p = 0.03)
compared with the empty vector strain ( Fig. 3 B). Similarly, L. lactis
clones bound more factor H when expressing SdrE ( p = 0.01) or Bbp ( p
< 0.01) compared with the empty vector strain ( Fig. 3 C). When the L.
lactis clones expressing SdrE were incubated in heated-sera and eval-
uated at 10 and 30 min, the amount of fH and C4BP bound did not sta-
tistically differ at either 10 min ( p = 0.7) or 30 min ( p = 0.09) ( Fig. 3 D).
These results suggest that in serum both factor H and C4BP are able
to bind SdrE expressed on a bacterial surface without either one pre-
venting the binding of the other. We then evaluated C4BP binding to
an SdrE-deﬁcient MRSA and control strains from the Nebraska Trans-
poson Mutant Library ( Fig. 3 E). These strains were incubated in 10%
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Fig. 4. Functional testing of complement-mediated opsonization and opsonophago- 
cytic killing of L. lactis expressing SdrE, or Bbp, or empty vector control. (A) C3-fragment 
opsonization of L. lactis strains incubated in 10% factor B-depleted sera for 30 min as- 
sayed by ELISA of stripped surface proteins ( n = 4). (B) Anti-C3 Western blot of stripped 
surface proteins from L. lactis clones incubated with 10% factor B-depleted serum. (C) 
Neutrophil killing of L. lactis strains incubated in 10% factor B-depleted sera and pu- 
riﬁed human neutrophils for the times indicated and then plated for colony counting 
( n = 4). Data are the means of results of independent experiments. Error bars denote 
SEM. eat-inactivated serum for 30 min, washed and stripped of surface- 
ound proteins were assayed for C4BP by dot blot. The SdrE-deﬁcient 
train showed a 30% ( p = 0.05) decrease in C4BP binding compared 
ith the wild-type. Similar C4BP binding to wild-type was found for 
he Sbi-deﬁcient, CHIPS-deﬁcient, and capsule-deﬁcient strains. 
.4. Classical complement pathway opsonization and bacterial killing. 
In order to evaluate the effect of bacterial expression of Bbp or 
drE on classical pathway mediated opsonization, we measured C3- 
ragment binding to L. lactis strains incubated in 10% factor B-depleted 
era ( Fig. 4 A). Factor B depleted serum was used to isolate activation 
o the classical and lectin pathways in the absence of the alterna- 
ive pathway. At 10 min, L. lactis expressing Bbp bound 47% fewer 
3-fragments compared with empty vector ( p = 0.05) and L. lactis ex- 
ressing SdrE bound 33% fewer C3-fragments compared with empty 
ector ( p = 0.03). C3-fragment binding comparing SdrE and Bbp 
lones were not statistically different. Anti-C3 Western bot analysis 
f stripped C3-fragments demonstrated that the bound C3-fragments 
ere opsonic forms C3b and iC3b ( Fig. 4 B). Anti-C3 Western blot anal- 
sis also suggested that the C3-fragments 75 kDa ( β), 68 kDa ( α′ 1 ), and 
2 kDa ( α′ 2 ) appeared more dense for the empty vector compared 
ith the SdrE / Bbp-expressing clones, consistent with quantitative 
LISA results. These results suggest that SdrE or Bbp mediated recruit- 
ent of C4BP to the bacterial surface signiﬁcantly decreased classical 
omplement pathway-mediated opsonization by C3-fragments. 
In order to evaluate the effect of bacterial expression of Bbp of 
drE on classical complement pathway mediated bacterial killing by 
eutrophils, we assayed survival or L. lactis strains incubated in 10% 
actor B-depleted serum incubated with human neutrophils ( Fig. 4 C). 
aseline controls were performed by incubating L. lactis in 10% factor 
-depleted serum without neutrophils. At 15 min, L. lactis expressing 
bp showed a 44% decrease in bacterial killing compared with empty 
ector ( p < 0.01) and L. lactis expressing SdrE demonstrated a 50% 
ecrease in killing compared with empty vector ( p < 0.01). At 30 min, 
. lactis expressing Bbp showed a 29% decrease in bacterial killing 
ompared with empty vector ( p = 0.04) and L. lactis expressing SdrE 
emonstrated a 49% decrease in killing compared with empty vector 
 p = 0.01). These data suggest that bacterial expression of Bbp or 
drE signiﬁcantly increase bacterial survival of classical complement 
athway-mediated neutrophil killing. 
. Discussion 
These experiments identify SdrE and Bbp as S. aureus cell wall 
roteins that bind the host classical complement pathway regulator 
4BP. SdrE and Bbp belong to the structurally related Sdr family of S. 
ureus proteins named for a repeating region of serine and aspartic 
cid (SD) dipeptides proximal to their LPXTG cell wall linkage [ 25 ]. 
drE has been implicated in platelet activation [ 26 ] and recently iden- 
iﬁed as a ligand for factor H [ 32 ]. Bbp, an allelic variant of SdrE [ 28 ],
as previously been noted to bind ﬁbrinogen and bone sialoprotein, 
or which it was named [ 35 ]. 
The distribution of sdrE has previously been reported to be as high 
s 90%, including nasal carriage, invasive strains, and MRSA strains 
 31 ]. Another study evaluating sdrE and bbp among invasive isolates 
ound 56% and 38% prevalence, respectively, for a combined 94% [ 28 ]. 
hese studies demonstrate that SdrE and Bbp are highly prevalent 
mong clinical isolates and suggest they likely play an important role 
n infection. 
Immunization studies were previously conducted in mice by 
tranger-Jones et al. using 19 different recombinantly expressed S. 
ureus surface proteins [ 34 ]. These studies showed that rSdrE was 
ne of the most effective immunogens in reducing S. aureus colony 
ounts ( > 4 logs) in mouse kidneys. Of the effective surface protein 
mmunogens, rSdrE immunization yielded serum with the highest level of complement-mediated opsonophagocytic killing of S. aureus . 
These studies suggest that in mice SdrE is an excellent immunogen 
against S. aureus and this effect is likely mediated, at least in part, by 
increasing complement-mediated opsonophagocytosis. Our ﬁndings 
show that bacterial surface expression of SdrE / Bbp increases recruit- 
ment of C4BP and decreases classical complement pathway-mediated 
opsonization and bacterial killing. Thus, our results are congruent 
with those of Stranger-Jones et al. and suggest that the effectiveness 
of SdrE as a protective immunogen may have been mediated, in part, 
via altering its interaction with C4BP. 
We have previously identiﬁed SdrE as a factor H-binding pro- 
tein and shown that bacterial expression of SdrE decreases alter- 
native complement pathway-mediated opsonization, anaphylatoxin 
production, and bacterial killing [ 32 ]. Here we show that bacteria ex- 
pressing SdrE are able to recruit factor H and C4BP simultaneously 
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 from human serum without evidence of interference. This suggests
that SdrE may play a vital role in the modulation of classical and al-
ternative pathway activation on the S. aureus surface via C4BP and
factor H, respectively. Thus, SdrE / Bbp appears to be attractive tar-
gets to inhibit these mechanisms of immune evasion and optimize
complement-mediated opsonophagocytosis and killing of S. aureus . 
Our ﬁndings show that SdrE / Bbp-mediated binding of C4BP in-
hibits classical complement pathway activation and subsequent op-
sonization and bacterial killing. Inhibition of antibody-initiated com-
plement activation likely contributes, in part, to lack of effective pro-
tective immunity after S. aureus infection or immunization. Disrup-
tion of SdrE / Bbp-mediated recruitment of C4BP will likely improve
antibody-initiated complement effectors and could prove an effective
strategy to improve anti- S. aureus vaccine development. 
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